TTR Amyloidosis disease is slowly gaining recognition particularly in New Zealand but in overseas countries such as in America and Europe, research work have been ongoing for years now to not only be able to produce more treatment options for patients but equally important, the understanding and comprehension of what this disease is about so that early diagnosis can be achieved and more awareness within the patient and medical body can be accomplished.
For this reason, the UK ATTR Patient Association recently hosted a webinar session with two leading experts in the world of amyloidosis treatment and research; Professor Mary M. Reilly who is the Professor of Clinical Neurology at University College London as well as head of Neurology and Neurosurgery, and also Professor Julian Gilmore, the clinical lead at London’s National Amyloidosis Centre speaking on cardiomyopathy..
In this video session with Professor Reilly, she succinctly explains in lay-person terms:
- What is amyloid?
- What is TTR?
- What are the effects of TTR deposit on the sensory and motor nerves?
- Why the importance pf early diagnosis and treatment of neuropathy and how can we accomplish this?
- What are the effects of TTR on the autonomic nervous system? What is autonomic neuropathy?
- What are the autonomic nervous system in our body?
- What is the deference between autonomic and peripheral nervous system?
- Why do some of us experience carpal tunnel syndrome? What is connective tissue disorder?
- What are the various mutation types and how treatment can differ between the subtypes?
- What are the symptoms like?
- What are the treatment options available? What are the various forms of treatment? What are the symptomatic treatment and how can patients manage the pain?
- Why early diagnosis is important?